UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549-1004
FORM 8-K
CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF
THE SECURITIES EXCHANGE ACT OF 1934
DATE OF REPORT (date of
earliest event reported): JULY 10, 2007
CIPHERGEN BIOSYSTEMS, INC.
(Exact name of Registrant as specified in its charter)
| |
|
|
|
|
Delaware
(State or other jurisdiction of
incorporation or organization)
|
|
000-31617
(Commission
File Number) |
|
33-059-5156
(I.R.S. Employer
Identification Number) |
6611 Dumbarton Circle
Fremont, CA 94555
(Address of principal executive offices)
(510) 505-2100
(Registrant’s telephone number, including area code)
Check the appropriate box below
if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2.):
o
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (7 CFR 240.13e-4(c))
TABLE OF CONTENTS
ITEM 1.01 ENTRY INTO A MATERIAL DEFINITIVE AGREEMENT
On July 10,
2007, Ciphergen Biosystems, Inc. (“Ciphergen”) entered into a license and
settlement agreement (the “Agreement”) with Health Discovery Corporation (“HDC”) (OTCBB:HDVY)
pursuant to which it licensed more than 25 patents covering HDC’s support vector machine technology
for use with SELDI technology. Under the terms of the Agreement, Ciphergen receives a worldwide,
royalty-free, non-exclusive license for life sciences and diagnostic applications of the technology
and has access to any future patents resulting from the underlying intellectual property in
conjunction with use of SELDI systems. Pursuant to the Agreement, Ciphergen will pay HDC a total of
$600,000, payable as follows: $200,000 upon entry into the agreement (the “Signing Date”), $100,000
three months following the Signing Date, $150,000 twelve months following the Signing Date and
$150,000 twenty-four months following the Signing Date. The agreement settles all disputes between
the companies.
The foregoing
description of the terms of the Agreement is qualified in its entirety by
reference to the copy of the Agreement, filed as Exhibit 10.1 to this report, and incorporated by
reference herein.
ITEM 7.01 REGULATION FD DISCLOSURE
The information
disclosed in Item 1.01 hereof is incorporated by reference into this item
7.01. A copy of Ciphergen’s press release announcing entry into
the Agreement is attached hereto as Exhibit 99.1 and is incorporated
herein by reference.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
(d) EXHIBITS.
| |
|
|
| EXHIBIT NO. |
|
DESCRIPTION |
10.1 |
|
Settlement Agreement dated July 10, 2007 between
Ciphergen Biosystems, Inc. and HDC |
|
|
|
99.1 |
|
Press release issued by Ciphergen Biosystems, Inc. on July 10, 2007 |